Our pipeline of differentiated antibody therapeutics targets well-established biological drivers and development pathways, with an initial focus on making impactful advancements in the treatment of atopic dermatitis and chronic obstructive pulmonary disease.
IDEAYA is a clinical-stage precision medicine oncology company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets. IDEAYA is headquartered in South San Francisco, California.
A new era for Peyronie's case
This combination has been proven to cause measurable and permanent reduction of penile fibrosis plaques. Our new pulsated gas and drug treatment technology has resulted in 15 patent filed or granted applications from our team of medical professionals and engineers.
EXO Sciences: Peyronie's Case Management
Did you know what you eat and drink has a huge impact on your Peyronie's disease?
Who knew there were sixteen variables that must be analyzed and closely managed to achieve curative outcomes with Peyronie's care?
Let's consider the Peyronie's facts:
- No one has ever been able to articulate the epidemiology of Peyronie's Disease, particularly for the most common cases (55%) where otherwise perfectly healthy men with no history of penile trauma awaken to awful Peyronie's symptoms without warning to go along with their morning erection.
- There has never been a cure.
- There has never been a treatment to effectively remove the fibrous plaques that cause penile curvature, lost length, hour glassing, indentions and erectile dysfunction.
- All existing remedies only treat the symptom of Peyronie's curvature when erectdisease.
- Long term success rates from existing Peyronie's treatments is only 15%-45%.
- A ten year retrospective study following Peyronie's surgery
Targeting the wrong problems
Why have so many attempts at a Peyronie’s solutions fallen flat? We believe it’s because they targeted the wrong problem.
Every traditional Peyronie’s care approach appears to have been invented using the concept that problem-solving equals invention. In other words, the penis becomes distorted from Peyronie’s in size or shape while it is erect, which is the Peyronie’s “problem”.
That would seem to imply…
If I manually straighten my Peyronie’s curvature through force with a traction device but the plaque that caused the curvature is still inside my penis, am I cured?
I’m good to go if my doctor injects a potent collagenase or enzymatic mixture into my penile plaque, softening it enough to physically straighten my organ?
Also, what about the numerous instances of Peyronie’s plaque and fibrosis in males who don’t exhibit these symptoms? The majority of such patients stated that they were often questioned about how “inconvenient” the problem was for them, even as their penile performance continued to decline.
Is it true that these latter patients do not have Peyronie’s Disease?
The Pathway to a Peyronie’s Cure: Symptoms
You cannot solve what you don’t understand.
The “problem” to be solved before developing an innovative medical procedure to cure Peyronie’s Disease was never within treating its many symptoms.
What are the symptoms of Peyronie’s Disease?
Symptoms include erect curvature, lost length, shaft indentions when engorged, lost sensation and erectile dysfunction.
The root problem is “What causes Peyronie’s Disease?”
How could we develop a permanent solution to healing Peyronie’s disease if we didn’t understand the details surrounding its underlying etiology? We didn’t think that was possible. We also felt this was the reason existing treatments came up short: they all medical procedures provided solutions to treat various Peyronie’s symptoms, never the removal of the basis for the disease itself.
During our twenty-year odyssey developing our breakthrough technology that permanently removes the fibrosis and penile plaques that trigger a Peyronie’s diagnosis, we found it imperative to develop a “working theory” regarding the etiology of Peyronie’s Disease.
Those working theories were mailable early on but became static over the last seven years as our technology began to prove effectual.
Our working hypothesis regarding the etiology of Peyronie’s Disease is multi-faceted and includes case and patient specific variables. It will require numerous future studies to achieve enhanced clinical accuracy.
However, we’ve reached a point using our working theory method in tandem with our treatment devices and protocols where, all, meaning 100% of Peyronie’s patients who are compliant and complete treatment with our technology see permanent reduction in penile fibrosis and plaques.
Imagine a disease…
That has existed for over 600 years
Where the incidence rate has risen by 300% among US men 45 years of age and under in the last decade, with an astounding 900% jump among 25 and under subset
Whose epidemiology remains misunderstood
That has never had a cure
Where the only remedies treat symptoms and their long-term success rate is only about 15%
This disorder is known as "Peyronie's Disease"
Imagine a company…
That invented a novel drug delivery technology that's clinically-proven proven to cause curative outcomes with Peyronie's
We're excited to introduce
EXO Biomedical has been issued five US patents for its novel blood flow drug delivery mechanism that transforms long-standing, marginally efficacious, generic drugs into "super drugs" with curative outcomes for Peyronie's Disease and a $29 billion "Serviceable Available Market" healthcare treatment market segment.
Currently, we generate revenue treating Peyronie's patients at our advanced medical facility in Atlanta, Georgia, utilizing our innovative technology as we investigate potential new opportunities related to this important breakthrough.
We plan to begin prospective clinical trials in 2025 and will subsequently file for FDA approval for our gas and drug injections in the treatment Peyronie's Disease in partnership with a large pharmaceutical company; our device and drugs combination are not yet available for sale to other doctors.
HOW TO PARTICIPATE
Have you seen the commercials about "do you have a curve"?
Penile curvature that manifests during an erection is a common sign of Peyronie's. Significant bending occurs in over 60% of Peyronie's case.
However, curvature is just one of the common symptoms. It is not the underlying cause or definition of this disease.
When a disease remains incurable for centuries, its symptoms almost always become society's definition of that disease.
Similarly, the efficacy of the treatments is measured by how well the symptoms are alleviated.
For example, this phenomenon is exemplified by the common cold. Coughing, sneezing, runny nose, sore throat and congestion are the most common symptoms, and people immediately assume we have a cold if we display these symptoms. Nobody inquiries about the type of virus we are fighting, such as rhinovirus, coronavirus, adenovirus, or enterovirus.
Since Peyronie's Disease has remained similarly incurable, it has likewise become only known for its symptoms, even among many physicians, with erect curvature being the most notable definition. Thus, every approved treatment and medication for Peyronies is evaluated solely based on its efficacy in reducing erect curvature.
This is what makes ExoSurge® completely different from anything ever used to treat Peyronie’s.
ExoSurge® technology treats, heals and cures the underlying disease of Peyronie’s, not just its symptoms.
Peyronie's Disease
An estimated 20-30% of men (globally) will suffer from Peyronie’s disease within the next twenty years. One-third of those will be unable to sexually perform without treatment.
Peyronie's Disease: U.S. Men Under Age 45
Whereas the historical percentage of younger men under the age of 45 years with palpable Peyronie’s fibrosis stayed relatively constant at around 3% for decades, that average has now jumped to 12%, representing a 300% among US men in that age group. The youngest subset included within the under age 45 group have seen the biggest rise in Peyronie's prevalence. Men under the age of 25 have seen Peyronie's prevalence rise from from 1.5% to 15%, an astounding 900% increase. All of this equates to a disease incidence rate that is increasing 20% every five years among US men under the age of forty-five.
Peyronie's Disease: US Men Age 45 And Over
The historical percentage of men aged 45 years and over old with a Peyronie’s indication also climbed, from 9% to 13%, a 44% increase.
Peyronie's Disease is an acquired inflammatory condition characterized by the accumulation of fibrous plaques within the penis most commonly as a result of years of micro trauma or a specific acute penile injury. It is progressive in nature and has detrimental effects on patients, including penile disfigurement and loss of sexual function, once symptoms are fully developed.
Numerous studies indicate that Peyronie's patients experience a significant increase in depression and a substantial decline in self-esteem.
Penile disfigurement
Loss of sexual function
Depression
Anxiety
Suicidal thoughts
We expect the permanent removal
of the fibrosis and plaques
associated with a Peyronie's diagnosis
to become a global challenge
for the medical industry in the years ahead.
ExoSurge® is the world's first clinically-proven treatment to permanently remove plaques and fibrosis associated with a Peyronie's diagnosis.
EXO's Peyronie's Business
On the basis of two recent disease prevalence studies involving over 19,000 American men, the current US (ATM) total addressable market exceeds $147 billion, of which a $29 billion segment is identified as the targeted (ASM) serviceable available market segment for our breakthrough technology.
The curative nature of our solution offers the potential for EXO to dominate this $29 billion marketplace.
Our Sciences
The ExoSurge® Inter-fibrinous Pulsated Gaseous Technology (IPG) uses a sequenced three-step drug injection and gaseous drug delivery process in every 20-minute treatment, which results in measurable and permanent reduction or softening of penile fibrosis. Our new pulsated gas and drug treatment technology has resulted in five issues US patents and another ten pending approval in the US and abroad from our team of medical professionals.
Our IPG technology delivers a treatment that is well tolerated, generates no heat or collateral tissue damage, requires no anesthesia, no patient downtime, and works without detrimental affect upon varied skin pigmentation.
IPG is a novel and distinctive method of drug administration. It has been clinically proven to transform generic intralesional Peyronie's medications into "super drugs" that produce curative results in which Peyronie's fibrosis is broken up and metabolized into the body.
Dive deeper into the technology and our plans for the future from the link below.
